ONP-002 — Topline data
Late 2026
The Phase IIa clinical data readout is projected before year-end 2026.Source filing
OGEN biotech catalysts & pipeline
ORAGENICS INC · Data as of 2026-09-08
Upcoming catalysts
ONP-002 — IND submission
Late 2026
Oragenics is currently reviewing these items and remains focused on its goal of submitting an Investigational New Drug (IND) application by the end of 2026.Source filing